Author's response to reviews

Title: Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.

Authors:

Wojciech Janczyk (w.janczyk@czd.pl)
Piotr Socha (p.socha@czd.pl)
Dariusz Lebensztejn (lebensztejn@hoga.pl)
Aldona Wierzbicka (aldona.wierzbicka@wp.pl)
Artur Mazur (drmazur@poczta.onet.pl)
Joanna Neuhoff-Murawska (gastrologia@gmail.com)
Pawel Matusik (endocrin@wp.pl)

Version: 4 Date: 3 May 2013

Author's response to reviews: see over
Cover letter for submission of manuscript

Wojciech Janczyk, M.D.
Dept. Gastroenterology, Hepatology and Eating Disorders
Children’s Memorial Health Institute
Al. Dzieci Polskich 20; 04-730 Warsaw, Poland
w.janczyk@czd.pl

MS: 3556153797865197

To

The Editors

BioMed Central Pediatrics

Dear Editors,

Recently we have submitted our manuscript “Omega-3 fatty acids vs placebo for treatment of non-alcoholic fatty liver disease in children – trial design” by Wojciech Janczyk et al. to the BioMed Central Pediatrics (MS: 3556153797865197). We followed your request to make some formal changes before your consideration.

Please find the addressed comments and changes described shortly below:

- We declare that our study received ethical approval and external funding. The study was awarded a grant from the Polish Ministry of Science and Higher Education. Bioethical Committee approval and the source of external funding are also mentioned in the “Acknowledgements” of the manuscript.
- As you asked, we have already sent the original and English translation of ethical and funding approvals to the Journal Editorial Office at editorial@biomedcentral.com. Contact persons are listed in the documents.
- Proof of external funding includes details of the amount of funding that was awarded for the study.
- We declare that we have not received any funding from commercial organization.
- We declare we have not submitted any manuscripts to any journals based on this study protocol.
- Our trial is registered in a publicly accessible registry: clinicaltrials.gov no. NCT01547910 (this information is also included in the abstract).
- Unique email addresses for all authors in the submission system have been provided
- CONSORT flowchart has been included in the manuscript as Figure 2.

We look forward to hearing from you at your earliest convenience.

With kind regards

Corresponding Author
Wojciech Janczyk